Diligence memo · auto-generated · as of July 3, 2026
Autolus Therapeutics plc
Autolus Therapeutics plc looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Autolus Therapeutics plc operates in Pharma, based in London.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Autolus Therapeutics plc has raised $200M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $200M on 2024-02-13.
Most recent recorded round closed around 2024-02-13.
Valuation (modeled)modeled
Provath models Autolus Therapeutics plc at approximately $2.4B (range $952M–$3.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.17× the median modeled value of Series D+ Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era. Within the normal band (117% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.4 yr ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 97% of Pharma peers (310 compared).
Modeled value ranks above 96% of those peers.
Closest niche peers: Mirador Therapeutics, Inc., Candid Therapeutics, Inc., Bluejay Therapeutics, Inc., Halda Therapeutics, LLC, Bright Peak Therapeutics, Inc..
Peoplefiled
17 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.